

Sr. No.	Particulars	Rupees in Lacs [except for share data]				
		9 Months Period ended on December 31, 2008 [Unaudited]	3 Months Period ended on March 31, 2009 [Audited]	Corresponding 3 Months Period ended in the previous year March 31, 2008 [Audited]	Year to date figures for the current year ended on March 31, 2009 [Audited]	Year to date figures for the previous year ended on March 31, 2008 [Audited]
1	Sales & Income from operations :					
A	Gross Sales	220,686	71,025	56,716	291,711	236,380
B	Less : Excise Duty	4,701	770	2,028	5,471	9,777
C	Net Sales	215,985	70,255	54,688	286,240	226,603
D	Other Income from Operations	4,424	2,085	1,464	6,509	5,685
E	Total sales and other income from operations	220,409	72,340	56,152	292,749	232,288
2	Expenditure :					
A	Increase [-] / Decrease [+] in stock in trade & work in progress	(7,515)	2,908	296	(4,607)	(4,552)
B	Consumption of materials	51,359	15,587	10,604	66,946	54,060
C	Purchase of traded goods	27,608	5,712	7,609	33,320	29,520
D	Employees cost	27,711	7,497	7,036	35,208	27,656
E	Depreciation & Amortisation	8,042	3,140	2,251	11,182	9,687
F	Other Expenditure	75,583	25,721	19,434	101,304	79,785
G	Total Expenditure	182,788	60,565	47,230	243,353	196,156
3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	37,621	11,775	8,922	49,396	36,132
4	Other Income	1,603	433	148	2,036	1,028
5	Profit before Interest & Exceptional Items [3 + 4]	39,224	12,208	9,070	51,432	37,160
6	A Interest & financial charges	5,379	4,399	1,079	9,778	5,223
B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	3,560	(1,290)	470	2,270	(1,090)
C	Total Financial cost	8,939	3,109	1,549	12,048	4,133
7	Profit after Interest but before Exceptional Items [5 - 6]	30,285	9,099	7,521	39,384	33,027
8	Exceptional Items	(182)	(2,226)	0	(2,408)	(691)
9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	30,103	6,873	7,521	36,976	32,336
10	Tax expense	5,076	1,582	2,005	6,658	6,126
11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	25,027	5,291	5,516	30,318	26,210
12	Extraordinary items [net of tax expense]	0	0	0	0	0
13	Net Profit [+] / Loss [-] for the period [11 - 12]	25,027	5,291	5,516	30,318	26,210
14	Adjustments on consolidation	(519)	509	(320)	(10)	(451)
15	Net Profit [+] / Loss [-] for the period [13 + 14]	24,508	5,800	5,196	30,308	25,759
16	Paid-up equity share capital [Face Value Rs. 5/-]	6,280	6,820	6,280	6,820	6,280
17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				116,700	99,940
18	Earnings Per Share [EPS] [For the period - not Annualised]:					
A	Basic and diluted EPS before Extraordinary items [Rs.]	17.95	4.25	4.14	22.20	20.51
B	Basic and diluted EPS after Extraordinary items [Rs.]	17.95	4.25	4.14	22.20	20.51
19	Public shareholding :					
	- Number of shares	35,138,950	34,629,818	35,150,458	34,629,818	35,150,458
	- Percentage of Shareholding	27.97%	25.37%	27.98%	25.37%	27.98%
20	Promoters and Promoter group Shareholding :					
A	Pledged / Encumbered :					
	- Number of Shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.	N.A.
	- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	N.A.
B	Non-encumbered :					
	- Number of Shares	90,474,758	101,869,195	90,463,250	101,869,195	90,463,250
	- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	100%	100%	100%	100%	100%
	- Percentage of shares [as a % of the total share capital of the company]	72.03%	74.63%	72.02%	74.63%	72.02%

Notes :

- [1] Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website : www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and/or NSE [www.nseindia.com].
- [2] The above audited results for the quarter and year ended March 31, 2009 were reviewed by the Audit Committee on April 27, 2009 and then approved by the Board of Directors at their meeting held on April 28, 2009.
- [3] In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited up to December 31, 2008 / February 28, 2009 and subject to limited review by their auditors for the balance period up to March 31, 2009.
- [4] During the quarter, 90,000,000 equity shares of Rs. 5/- each were cancelled and 100,885,305 equity shares of Rs. 5/- each were issued simultaneously pursuant to Composite Scheme of Arrangement and as a result, the paid up capital of the Company is increased to 136,499,013 equity shares of Rs. 5/- each fully paid up.
- [5] Pursuant to Composite Scheme of Arrangement becoming effective, the Consumer Products Division of the Company was demerged and transferred to Carnation Nutra Analogue Foods Ltd. [Name changed to Zydus Wellness Ltd.], a subsidiary of the Company, with appointed date April 1, 2008 & therefore, the figures of the current period / year are not exactly comparable with those of the previous period / year.
- [6] Hitherto the Company used to follow AS-11 read with the Schedule VI to the Companies Act, 1956, and used to write off all the amount of exchange rate difference arising from " Long Term Foreign Currency Monetary Items " [LTFECMI] to the Profit & Loss Account. The Company has opted for accounting the exchange rate differences arising on the LTFECMI in accordance with the notification dated March 31, 2009 under the Companies [Accounting Standards] Amendment Rules, 2009 on Accounting Standard 11 relating to " the effects of changes in foreign exchange rates ". In view of above change in policy, net profit, net of tax, of the company for the year is higher by Rs. 945 Lacs.
- [7] The Board of Directors have recommended a dividend of Rs. 4.50 per equity share on the increased capital of 136,499,013 equity shares of Rs. 5/- each for the financial year ended March 31, 2009.
- [8] The status of investor complaints :
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 19, pending at the end of the quarter - Nil.
- [9] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director